7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …

Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC
in terms of progression-free survival (PFS), objective response rate, tolerability and quality of …